How to slow ageing: the evidence-based methods that actually work

The most striking thing about the science of slowing ageing is how unglamorous the winners are. There is a large and growing industry built on the promise of exotic shortcuts — pills, peptides, cold plunges, proprietary stacks — but when you line the interventions up by the strength of their evidence, the ones at the top are the ones your grandmother would recognise: move your body, keep your muscle, eat mostly whole food, sleep enough, don't smoke, go easy on alcohol, stay connected to other people, and don't live in a permanent state of stress. What has changed is not the list. What has changed is that we can now put numbers on how much each one matters, and — for a handful of them — actually measure whether they are shifting the pace of ageing.

This article walks through the methods with the best human evidence for slowing ageing and extending healthspan, roughly in order of how strong that evidence is. Two honest caveats sit over the whole thing, and it is worth stating them up front rather than burying them. First, most of this evidence is observational — it shows that people who do these things tend to live longer and healthier, not always that the behaviour caused the longer life. Some of that association is real cause and effect; some of it is that healthier people find it easier to exercise, eat well and sleep, which flips the arrow. Where we have randomised trials — the design that can actually prove cause — we will say so explicitly, because they are the exception, not the rule. Second, effect sizes are population averages; no single study tells you what will happen to you.

1. Move your body — the single most reliable lever

If you could only change one thing, the evidence would point here. Physical activity is associated with lower mortality with unusual consistency across huge datasets, and — importantly — a lot of the benefit arrives at surprisingly modest doses.

A harmonised meta-analysis that pooled accelerometer data (movement measured by device, not self-report, which removes a major source of bias) from more than 36,000 adults found that people in the most active quarter had roughly a 50–70% lower risk of death over follow-up than the least active quarter, with the steepest gains coming as the most sedentary people started doing any regular light activity (Ekelund et al., 2019, BMJ). The same analysis found that prolonged sedentary time was itself associated with higher mortality — the most sedentary had more than double the risk of the least. The dose-response curve is steep at the bottom and flattens higher up: going from nothing to a little buys you more than going from a lot to slightly more.

The step-count literature tells the same story in a more intuitive unit. A meta-analysis of 15 international cohorts (n≈47,000) found mortality falling as daily steps rose, with the benefit plateauing at around 6,000–8,000 steps a day for adults over 60, and around 8,000–10,000 for younger adults — after which more steps kept helping, but with diminishing returns (Paluch et al., 2022, Lancet Public Health). The widely repeated "10,000 steps" figure turns out to be a reasonable target, not a magic threshold, and you capture most of the gain well before it.

Cardiorespiratory fitness — how efficiently your body uses oxygen — is the sharpest version of this signal. Higher measured fitness is associated with lower long-term mortality with no observed upper limit of benefit in the data (Mandsager et al., 2018, JAMA Network Open); we cover why in VO2 max as a longevity biomarker. The honest caveat: the fittest people are also, on average, healthier to begin with, so some of that association is reverse causation — but the accelerometer and randomised-exercise evidence make it very unlikely that movement is merely a marker of health rather than a cause of it. (One large pooled analysis put the practical ceiling in perspective: benefits continue at high volumes but the curve is essentially flat once you are well past the guideline minimum — Arem et al., 2015, JAMA Internal Medicine.)

2. Build and keep muscle

Aerobic movement gets most of the attention, but strength is a distinct lever with its own evidence, and it becomes more important with age as muscle mass naturally declines. A meta-analysis of 16 cohort studies found that muscle-strengthening activity was associated with a 10–17% lower risk of all-cause mortality, cardiovascular disease, and cancer — with a J-shaped curve where the benefit maxed out at a fairly small dose, around 30–60 minutes a week, and appeared to level off or slightly reverse at very high volumes (Momma et al., 2022, British Journal of Sports Medicine).

You can even see this in a single cheap measurement: grip strength. In the UK Biobank cohort of over half a million people, each 5 kg of lower grip strength was associated with roughly a 20% higher mortality risk in women and 16% in men, alongside higher cardiovascular and respiratory risk (Celis-Morales et al., 2018, BMJ). Grip strength is a proxy for whole-body muscle and neuromuscular health rather than something you train directly — but the direction is clear: preserving strength as you age tracks with living longer.

3. Eat a mostly whole-food, Mediterranean-style diet

Diet is where evidence quality gets messy — most nutrition studies are observational and confounded — so the strongest signals come from the rare randomised trials and from studies that track changes in diet over time.

The best randomised evidence is PREDIMED, a Spanish trial of 7,447 people at high cardiovascular risk. Assigning people to a Mediterranean diet supplemented with extra-virgin olive oil or with nuts reduced major cardiovascular events by roughly 30% versus a control low-fat diet (Estruch et al., 2018, NEJM). An important honesty note: this is the 2018 re-analysis and republication of the trial — the original 2013 paper was retracted and re-issued after irregularities in how some participants were randomised were discovered; the corrected analysis reached the same conclusion, but you should know the history rather than have it hidden from you.

The observational side is strengthened by studies of dietary change. Following nearly 74,000 US health professionals, people whose diet quality improved over 12 years had a lower risk of death than those whose diet stayed the same or worsened — a 20% improvement in diet-quality score was associated with an 8–17% lower mortality risk (Sotos-Prieto et al., 2017, NEJM). The practical read: the specific "diet" label matters less than the pattern — more plants, legumes, fish, nuts and olive oil; less ultra-processed food, refined sugar and processed meat — and it is never too late to start, because improvement itself tracked with benefit. This pattern is also the most reliable everyday lever on the metabolic and inflammatory markers that drive ageing, like HbA1c (blood sugar and ageing) and hs-CRP (inflammation and ageing).

4. Eating patterns: what caloric restriction and fasting really show

This is the area with the most hype and the most nuance, so it is worth separating what the trials actually found from what the internet claims.

Sustained caloric restriction has the strongest supporting data — and it is genuinely landmark. CALERIE was a randomised controlled trial in which healthy, non-obese adults cut calories by a target of 25% for two years. The restriction group showed a measurably slower pace of biological ageing on the DunedinPACE epigenetic clock — on the order of a 2–3% slowing (Waziry et al., 2023, Nature Aging). This is one of the first randomised human demonstrations that a lifestyle intervention can shift a validated pace-of-ageing clock. The caveats matter, though: the effect was small, it showed up on the pace clock (DunedinPACE) but not on the two static biological-age clocks (PhenoAge, GrimAge) measured in the same trial, and sustaining a 25% calorie cut for years is difficult and not appropriate for everyone — particularly older adults or anyone at risk of losing muscle or bone.

Time-restricted eating — the popular "16:8" version of intermittent fasting — has weaker evidence than its popularity suggests. In the randomised TREAT trial, restricting eating to an 8-hour window produced no significant weight or metabolic benefit over simply eating across the normal day, and there was a signal of greater lean-mass (muscle) loss in the fasting group (Lowe et al., 2020, JAMA Internal Medicine). This is a genuine null result worth taking seriously: the clock-time window itself did not appear to be the active ingredient. The honest synthesis is that what and how much you eat has far stronger evidence than when — and if you do try time-restricted eating, guard your protein and resistance training so you are not trading fat for muscle.

5. Protect your sleep

Sleep behaves like a dose-response curve with a sweet spot rather than "more is always better." A meta-analysis pooling more than 1.3 million participants found a U-shaped relationship: both short sleep (a ~12% higher mortality risk) and long sleep (a ~30% higher risk) were associated with worse outcomes than sleeping around 7 hours (Cappuccio et al., 2010, Sleep). A later dose-response meta-analysis confirmed the U-shape, with the lowest risk clustering around 7 hours a night (Yin et al., 2017, JAHA).

The caveat here is unusually important. The long-sleep association is heavily confounded by reverse causation — people who sleep 9–10 hours are frequently doing so because of underlying illness, depression or frailty, so long sleep is often a symptom rather than a cause. The short-sleep side has more plausible mechanisms (metabolic, inflammatory and cardiovascular disruption from chronic sleep restriction). The safe, evidence-consistent target is to protect roughly 7–8 hours of good-quality sleep, and to treat persistently needing far more as a reason to look for an underlying cause rather than a longevity strategy in itself.

6. Don't smoke — and if you do, quitting works fast

This is the closest thing in the entire field to a settled, causal result, and the effect size dwarfs almost everything else on this list. In a study of more than 200,000 US adults, smokers had roughly three times the mortality rate of never-smokers and lost, on average, more than a decade of life (Jha et al., 2013, NEJM). The famous 50-year follow-up of British doctors reached the same conclusion decades earlier: lifelong smoking cost around ten years of life (Doll et al., 2004, BMJ).

The genuinely hopeful part is how reversible it is. In the same US data, quitting before age 40 avoided roughly 90% of the excess mortality risk from continued smoking — and quitting at any age produced meaningful gains. Unlike most items here, this one is not a subtle association buried in noise: it is one of the largest, most consistent and most causally secure effects in all of longevity epidemiology.

7. Be careful with alcohol

The old story that a daily glass of red wine is good for you has not survived larger and better analyses. The Global Burden of Disease alcohol study, pooling data across 195 countries, concluded that the level of alcohol consumption that minimises harm to overall health is zero (GBD 2016 Alcohol Collaborators, 2018, Lancet). Earlier studies that appeared to show a protective effect at low doses were substantially confounded — for instance, by "sick quitters" (people who had stopped drinking because they were already ill) inflating the risk of the abstainer group.

In fairness, the nuance: this analysis weighed total health burden, and alcohol's harms include causes (like injury and certain cancers) that dominate at the population level even when a small cardiovascular signal exists for some individuals. The practical, evidence-aligned message is not prohibition but honesty: there is no dose of alcohol that has been shown to improve longevity, and less is reliably better than more.

8. Stay socially connected

Social connection is easy to dismiss as soft, but its mortality evidence is quantitatively on par with the classic physical risk factors. A meta-analysis of 148 studies covering more than 300,000 people found that stronger social relationships were associated with a 50% greater likelihood of survival over the study periods — an effect size comparable to quitting smoking and larger than obesity or physical inactivity (Holt-Lunstad et al., 2010, PLoS Medicine).

A follow-up meta-analysis focused specifically on the flip side — isolation and loneliness — and found that social isolation (odds ratio ~1.29), loneliness (~1.26) and living alone (~1.32) were each associated with significantly increased mortality risk (Holt-Lunstad et al., 2015, Perspectives on Psychological Science). The caveat is the familiar one: this is observational, and ill or depressed people may withdraw socially, so some of the arrow runs the other way. But the consistency across studies, and plausible biological pathways through chronic stress and inflammation, make connection a lever worth taking as seriously as diet or exercise.

9. Manage chronic stress

Chronic psychological stress leaves a measurable biological mark, and one of the clearest is at the level of telomeres — the protective caps on your chromosomes whose shortening is one of the hallmarks of ageing. In a landmark study, women under the highest chronic stress (caregivers of chronically ill children) had telomeres shorter by the equivalent of roughly a decade of additional ageing compared with low-stress women (Epel et al., 2004, PNAS).

The link generalises. A meta-analysis of 41 studies covering more than 30,000 people found that early-life adversity was reliably associated with shorter telomeres in adulthood (Ridout et al., 2018, Molecular Psychiatry). Two honest caveats: the original Epel study was small (n=58), and telomere length is a noisy, indirect marker rather than a clock you should track obsessively. But the direction is consistent across a large literature, and the practical implication is uncontroversial — chronic, unmanaged stress is a plausible accelerant of biological ageing, and the tools that reduce it (sleep, exercise, social connection, and where needed professional support) overlap heavily with the rest of this list.

10. Investigational pharmacology — promising, but not for a blog to prescribe

Finally, the frontier. Two drugs come up repeatedly as candidate "geroprotectors," and it is worth understanding both the promise and the very large asterisk.

A rapamycin analogue (an mTOR inhibitor) improved the immune response to vaccination in older adults in a randomised trial — a real, controlled signal that a drug can improve a marker of immune ageing (Mannick et al., 2014, Science Translational Medicine). And metformin, the common diabetes drug, is the basis of the proposed TAME trial designed to test directly whether it slows ageing-related disease (Barzilai et al., 2016, Cell Metabolism).

This is where the caveats become the headline. These are investigational for ageing specifically — not approved anti-ageing treatments. The rapamycin result was about a vaccine-response biomarker, not lifespan. The metformin trial (TAME) is a rationale and proposal; at the time of writing it remains unfunded and unlaunched, with no completed registered outcome trial of metformin for ageing in healthy people. Both drugs carry real side effects and belong firmly in the domain of a clinician and a monitored trial, not self-experimentation. The honest state of play: genuinely exciting science, no established pill.

How to read this list sensibly

A few principles keep this from turning into anxiety or magical thinking. The order matters: not smoking, regular movement and preserving muscle sit at the top because their evidence is strongest and their effects largest — start there before optimising the exotic tail. Beware reverse causation: for every observational lever here, healthier people find the behaviour easier, so real effects are almost always somewhat smaller than the raw association suggests; we have flagged where randomised trials shore this up (exercise, Mediterranean diet, caloric restriction, smoking cessation). The levers overlap: movement improves sleep, sleep improves stress, connection buffers stress, diet moves your metabolic markers — you are not really choosing between them, you are compounding them. And measure the trend, not the miracle: the point of tracking markers like HbA1c, hs-CRP, ApoB (why ApoB beats LDL for heart risk) and your biological age is to see whether these habits are actually working for you, over time, rather than trusting that they must be.

The bottom line

There is no proven pill for ageing, but there is an unusually consistent playbook, and its most important entries are the least surprising. Move regularly and keep some muscle. Eat mostly whole food in a Mediterranean-style pattern. Protect around seven to eight hours of sleep. Don't smoke, go easy on alcohol, stay connected to people, and keep chronic stress in check. None of these is a silver bullet, and each comes with honest limits — but they stack, they are cheap, they are largely within your control, and for several of them we can now measure whether they are shifting your pace of ageing. That combination — familiar habits, made visible — is the real state of the art in slowing how you age.

Sources

1. Ekelund U, Tarp J, Steene-Johannessen J, et al. Dose-response associations between accelerometry measured physical activity and sedentary time and all cause mortality: systematic review and harmonised meta-analysis. BMJ. 2019;366:l4570. PMID 31434697 · DOI 10.1136/bmj.l4570.
2. Paluch AE, Bajpai S, Bassett DR, et al. Daily steps and all-cause mortality: a meta-analysis of 15 international cohorts. Lancet Public Health. 2022;7(3):e219–e228. PMID 35247352 · DOI 10.1016/S2468-2667(21)00302-9.
3. Arem H, Moore SC, Patel A, et al. Leisure time physical activity and mortality: a detailed pooled analysis of the dose-response relationship. JAMA Internal Medicine. 2015;175(6):959–967. PMID 25844730 · DOI 10.1001/jamainternmed.2015.0533.
4. Momma H, Kawakami R, Honda T, Sawada SS. Muscle-strengthening activities are associated with a lower risk of all-cause, cardiovascular disease, and cancer mortality: a systematic review and meta-analysis of cohort studies. British Journal of Sports Medicine. 2022;56(13):755–763. PMID 35228201 · DOI 10.1136/bjsports-2021-105061.
5. Celis-Morales CA, Welsh P, Lyall DM, et al. Associations of grip strength with cardiovascular, respiratory, and cancer outcomes and all cause mortality: prospective cohort study of half a million UK Biobank participants. BMJ. 2018;361:k1651. PMID 29739772 · DOI 10.1136/bmj.k1651.
6. Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. New England Journal of Medicine. 2018;378(25):e34. PMID 29897866 · DOI 10.1056/NEJMoa1800389.
7. Sotos-Prieto M, Bhupathiraju SN, Mattei J, et al. Association of changes in diet quality with total and cause-specific mortality. New England Journal of Medicine. 2017;377(2):143–153. PMID 28700845 · DOI 10.1056/NEJMoa1613502.
8. Waziry R, Ryan CP, Corcoran DL, et al. Effect of long-term caloric restriction on DNA methylation measures of biological aging in healthy adults: the CALERIE trial. Nature Aging. 2023;3(3):248–257. PMID 37118425 · DOI 10.1038/s43587-022-00357-y.
9. Lowe DA, Wu N, Rohdin-Bibby L, et al. Effects of time-restricted eating on weight loss and other metabolic parameters in women and men with overweight and obesity: the TREAT randomized clinical trial. JAMA Internal Medicine. 2020;180(11):1491–1499. PMID 32986097 · DOI 10.1001/jamainternmed.2020.4153.
10. Cappuccio FP, D'Elia L, Strazzullo P, Miller MA. Sleep duration and all-cause mortality: a systematic review and meta-analysis of prospective studies. Sleep. 2010;33(5):585–592. PMID 20469800 · DOI 10.1093/sleep/33.5.585.
11. Yin J, Jin X, Shan Z, et al. Relationship of sleep duration with all-cause mortality and cardiovascular events: a systematic review and dose-response meta-analysis of prospective cohort studies. Journal of the American Heart Association. 2017;6(9):e005947. PMID 28889101 · DOI 10.1161/JAHA.117.005947.
12. Jha P, Ramasundarahettige C, Landsman V, et al. 21st-century hazards of smoking and benefits of cessation in the United States. New England Journal of Medicine. 2013;368(4):341–350. PMID 23343063 · DOI 10.1056/NEJMsa1211128.
13. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ. 2004;328(7455):1519. PMID 15213107 · DOI 10.1136/bmj.38142.554479.AE.
14. GBD 2016 Alcohol Collaborators. Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2018;392(10152):1015–1035. PMID 30146330 · DOI 10.1016/S0140-6736(18)31310-2.
15. Holt-Lunstad J, Smith TB, Layton JB. Social relationships and mortality risk: a meta-analytic review. PLoS Medicine. 2010;7(7):e1000316. PMID 20668659 · DOI 10.1371/journal.pmed.1000316.
16. Holt-Lunstad J, Smith TB, Baker M, Harris T, Stephenson D. Loneliness and social isolation as risk factors for mortality: a meta-analytic review. Perspectives on Psychological Science. 2015;10(2):227–237. PMID 25910392 · DOI 10.1177/1745691614568352.
17. Epel ES, Blackburn EH, Lin J, et al. Accelerated telomere shortening in response to life stress. Proceedings of the National Academy of Sciences. 2004;101(49):17312–17315. PMID 15574496 · DOI 10.1073/pnas.0407162101.
18. Ridout KK, Levandowski M, Ridout SJ, et al. Early life adversity and telomere length: a meta-analysis. Molecular Psychiatry. 2018;23(4):858–871. PMID 28322278 · DOI 10.1038/mp.2017.26.
19. Mannick JB, Del Giudice G, Lattanzi M, et al. mTOR inhibition improves immune function in the elderly. Science Translational Medicine. 2014;6(268):268ra179. PMID 25540326 · DOI 10.1126/scitranslmed.3009892.
20. Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. Metformin as a tool to target aging. Cell Metabolism. 2016;23(6):1060–1065. PMID 27304507 · DOI 10.1016/j.cmet.2016.05.011.

This article is for education only and is not medical advice. See our medical disclaimer.